Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,361 to 1,380 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Adults on CSII Treatment vs Paediatric Patients on CSII Treatment: Number of Patients With HbA1c on Target Using Advanced Pump's Functions, CGM and CHO Counting | 1,713 of 5,598 515 of 1,025 | -19.6 points -22.9 to -16.4 | 6,623 | NCT02620917 Continuos Subcutaneous Insulin Infusion in Italy |
| Adults on CSII Treatment vs Paediatric Patients on CSII Treatment: Number of Patients With Glycated Hemoglobin on Target | 1,288 of 5,598 445 of 1,025 | -20.4 points -23.6 to -17.2 | 6,623 | NCT02620917 Continuos Subcutaneous Insulin Infusion in Italy |
| Palivizumab vs Motavizumab: Number of Participants Reporting Any Related AEs | 258 of 3,298 298 of 3,315 | -1.2 points -2.5 to 0.2 | 6,613 | NCT00129766 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
| Palivizumab vs Motavizumab: Number of Participants Reporting Any Related SAEs | 8 of 3,298 9 of 3,315 | -0.0 points -0.3 to 0.2 | 6,613 | NCT00129766 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
| Palivizumab vs Motavizumab: Number of Participants Reporting Any Adverse Events (AEs) | 2,837 of 3,298 2,839 of 3,315 | 0.4 points -1.3 to 2.1 | 6,613 | NCT00129766 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
| Palivizumab vs Motavizumab: Number of Participants Who Discontinued Study Drug Due to AEs | 10 of 3,298 13 of 3,315 | -0.1 points -0.4 to 0.2 | 6,613 | NCT00129766 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
| Palivizumab vs Motavizumab: Number of Participants Reporting Any Serious Adverse Events (SAEs) | 506 of 3,298 485 of 3,315 | 0.7 points -1.0 to 2.4 | 6,613 | NCT00129766 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
| Palivizumab vs Motavizumab: Number of Participants Who Died | 4 of 3,298 8 of 3,315 | -0.1 points -0.4 to 0.1 | 6,613 | NCT00129766 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
| Palivizumab vs Motavizumab: serious adverse events | 506 of 3,298 485 of 3,315 | 0.7 points -1.0 to 2.4 | 6,613 | NCT00129766 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
| Empagliflozin 10 mg vs Placebo: deaths from any cause | 314 of 3,304 353 of 3,305 | -1.2 points -2.6 to 0.3 | 6,609 | NCT03594110 EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) |
| Empagliflozin 10 mg vs Placebo: serious adverse events | 1,089 of 3,304 1,167 of 3,305 | -2.4 points -4.6 to -0.1 | 6,609 | NCT03594110 EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) |
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major Amputation Due to a Vascular Etiology | 508 of 3,286 584 of 3,278 | -2.4 points -4.2 to -0.6 | 6,564 | NCT02504216 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities |
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Participants With Composite of MI, Ischemic Stroke, All-cause Mortality (ACM), ALI, and Major Amputation of a Vascular Etiology | 614 of 3,286 679 of 3,278 | -2.0 points -4.0 to -0.1 | 6,564 | NCT02504216 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities |
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Participants With Composite of MI, Ischemic Stroke, Coronary Heart Disease (CHD) Death, ALI, and Major Amputation of a Vascular Etiology | 433 of 3,286 528 of 3,278 | -2.9 points -4.6 to -1.2 | 6,564 | NCT02504216 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities |
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Participants With Composite of MI, All-cause Stroke, Cardiovascular (CV) Death, Acute Limb Ischemia (ALI), and Major Amputation of a Vascular Etiology | 514 of 3,286 588 of 3,278 | -2.3 points -4.1 to -0.5 | 6,564 | NCT02504216 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities |
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Participants With Hospitalization for a Coronary or Peripheral Cause (Either Lower Limb) of a Thrombotic Nature | 262 of 3,286 356 of 3,278 | -2.9 points -4.3 to -1.5 | 6,564 | NCT02504216 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities |
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Mortality (All-cause) | 321 of 3,286 297 of 3,278 | 0.7 points -0.7 to 2.1 | 6,564 | NCT02504216 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities |
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Participants With an Unplanned Index Limb Revascularization for Recurrent Limb Ischemia (Subsequent Index Leg Revascularization That Was Not Planned or Considered as Part of the Initial Treatment Plan at the Time of Randomization) | 584 of 3,286 655 of 3,278 | -2.2 points -4.1 to -0.3 | 6,564 | NCT02504216 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities |
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Participants With Venous Thromboembolic (VTE) Events | 25 of 3,286 41 of 3,278 | -0.5 points -1.0 to -0.0 | 6,564 | NCT02504216 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities |
| Active Vitamin E vs Vitamin E Placebo: Effect of Vitamin E on CRA Occurrence, Analyzed by Active Vitamin E vs. Vitamin E Placebo | 1,159 of 3,269 1,127 of 3,277 | 1.1 points -1.2 to 3.4 | 6,546 | NCT00706121 S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000 |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=69
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02620917-48356c6e",
"title": "Adults on CSII Treatment vs Paediatric Patients on CSII Treatment: Number of Patients With HbA1c on Target Using Advanced Pump's Functions, CGM and CHO Counting",
"summary": "1713 of 5598 against 515 of 1025; risk difference -19.6 points, 95% interval -22.9 to -16.4; NCT02620917, Continuos Subcutaneous Insulin Infusion in Italy",
"record": "/library/comparisons/NCT02620917-48356c6e",
"nct_id": "NCT02620917",
"kind": "outcome",
"participants": 6623,
"risk_difference": {
"value": -0.19643688076752153,
"lower": -0.2292289188169661,
"upper": -0.16353015332702361
},
"group_1": "1,713 of 5,598",
"group_2": "515 of 1,025",
"difference": "-19.6 points",
"interval": "-22.9 to -16.4",
"trial_title": "Continuos Subcutaneous Insulin Infusion in Italy"
},
{
"id": "NCT02620917-aa213537",
"title": "Adults on CSII Treatment vs Paediatric Patients on CSII Treatment: Number of Patients With Glycated Hemoglobin on Target",
"summary": "1288 of 5598 against 445 of 1025; risk difference -20.4 points, 95% interval -23.6 to -17.2; NCT02620917, Continuos Subcutaneous Insulin Infusion in Italy",
"record": "/library/comparisons/NCT02620917-aa213537",
"nct_id": "NCT02620917",
"kind": "outcome",
"participants": 6623,
"risk_difference": {
"value": -0.20406416925905593,
"lower": -0.23646370797639502,
"upper": -0.17200012098806894
},
"group_1": "1,288 of 5,598",
"group_2": "445 of 1,025",
"difference": "-20.4 points",
"interval": "-23.6 to -17.2",
"trial_title": "Continuos Subcutaneous Insulin Infusion in Italy"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=70",
"request_id": "fcBFqtGhV2BIetLq"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant